Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-05-14

FDA Approved: GAVILYTE-H AND BISACODYL — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Gavilyte-H and Bisacodyl, a combination laxative tablet containing polyethylene glycol 3350 with electrolytes an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bisacodyl (bisacodyl)
  • GAVILYTE-H (Polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride)

Snippet

SUPPL AP for GAVILYTE-H AND BISACODYL (POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL DELAYED-RELEASE TABLET)